Oncology Could Give Gutsy Biotechs Another Chance [Seeking Alpha]
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: Seeking Alpha
Companies focusing on the gut microbiome were dealt a serious blow last year with Seres’ (NASDAQ: MCRB ) phase II failure, but now a small study could reinvigorate the field. The trial looks like the first to show in humans that response to the anticancer checkpoint blockade could be determined by the composition of patients’ gut bacteria. Most biotech start-ups in this field have focused on more obvious applications, like treating bacterial and gastrointestinal diseases – strategies that have brought in over $600m of financing (see table below). But immuno-oncology offers a new avenue, and two players, Synlogic and Evelo Biosciences, already have an early focus here. Of course, a link between the microbiome – the genetic makeup of the microbes in the human body – and diseases from asthma to multiple sclerosis has been postulated for some time. But its role in cancer immunotherapy, while intriguing, was a very early hypothesis. Indeed, the only recent evidence backing it
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Microbiome Manufacturing Market Trends and Global Forecasts, 2035 - Close to 170 Trials are Evaluating Microbiome Therapeutics to Treat Various Infectious Diseases and Oncological Disorders [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $9.00 to $5.00. They now have an "outperform" rating on the stock.MarketBeat
MCRB
Earnings
- 11/2/23 - Beat
MCRB
Sec Filings
- 3/27/24 - Form 4
- 3/27/24 - Form 3
- 3/5/24 - Form DEF
- MCRB's page on the SEC website